log
     Login   |   Register   
img
 
EDITORIAL BOARD
 
  Dr. ONOFRIO LASELVA  
 
Address 1 :
Address 2 :
Title : Dr.
First Name : ONOFRIO
Last Name : LASELVA
University/Institution : The Hospital for Sick Children
Email ID : onofrio.laselva@sickkids.ca
City : Toronto
Country : Canada
State : Ontario
Zipcode : M5G 0A4
Department : Molecular Medicine
Company Name :
Area of Research
Personalized medicine for Cystic Fibrosis patients
Area of Expertise
Cell biology, physiology, biochemistry
Brief Description of Research Interest :
My research focus is in Cell Biology and Personalized Medicine for Cystic Fibrosis patients, with some expertise in Biochemistry and Molecular Biology. In particular, I'm interested to study the mechanism of action of small CFTR modulators. Therefore, I'm testing efficacy of these new small molecules in primary nasal epithelial cells or iPS cells differentiated to lung cells from patient bearing the most common CFTR mutation (F508del) and other rare mutations.
Representative Publications :

1)  LASELVA O., DU K, BEAR C.E Activity of Lumacaftor is not conserved in zebrafish Cftr bearing major CF-causing mutation (FASEB J, in revision)

2)  LASELVA O., MARZARO G., VACCARIN C., LAMPRONTI I., TAMANINI A., LIPPI G., GAMBARI R., CABRINI G., BEAR C.E., CHILIN A., DECHECCHI M.C.;Molecular mechanism of action of Trimethylangelicin derivatives as CFTR modulators(Frontiers in Pharmacology, 2018)

3)  LASELVA O., MOLINSKI S., CASAVOLA V., BEAR C.E. Correctors of the major Cystic Fibrosis mutant interact through membrane spanning domains (Molecular Pharmacology, 2018

4)  MOLINSKI S., SHAHANI V., SUBRAMANIAN A., MACKINNON S., WOOLLARD G., LAFORET M., LASELVA O., MORAYNISS L., BEAR C.E., WINDEMUTH A., Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site (Proteins: Structure, Function, and Bioinformatics, 2018)

5)  MOLINSKI S., AHMADI S., KULLEPERUMA K., IP W., OUYANG H., VILLELLA A., MILLER J.P., LEE P.S, KULLEPERUMA K., DU K, DI PAOLA M., ECKFORD P., LASELVA O., HUAN L.J., WELLHAUSER L, LI E., RAY P.N, MORAES T.J. GONSKA T., RATJEN F, BEAR C.E. ORKAMBI/amplifier co-therapy rescues a rare CFTRmutation in gene-edited cells and patient tissue (Embo Molecular Medcine, 2017)

6)    LASELVA O., MOLINSKI S., CASAVOLA V., BEAR C.E. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain (Biochemical Pharmacology Journal, 2016)

7)    ABBATTISCIANNI A.C., FAVIA M, MANCINI M.T., CARDONE R.A., GUERRA L., MONTERISI S., CASTELLANI S., LASELVA O., DI SOLE F., CONESE M., ZACCOLO M., CASAVOLA V. “Correctors of mutant CFTR enhance subcortical cAMP/PKA signaling via ezrin phosphorylation and cytoskeleton organization (Journal of Cell Science, 2016)

8)    FAVIA M, MANCINI MT, BEZZERRI V, GUERRA L, LASELVA O, ABBATTISCIANNI A.C, RESHKIN SJ, GAMBARI R, CABRINI G, CASAVOLA V. Trimethylangelicin promotes the functional rescue of F508del CFTR in CF airway cells. (Am J Physiol Lung Cell Mol Physiolgy 2014)

 
     
 
 
footer